---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-23-000765"
form_type: "8-K"
ticker: "LIPO"
cik: "0001347242"
company_name: "LIPELLA PHARMACEUTICALS INC."
filed_at: "2023-06-01T23:59:59+00:00"
generated_at: "2026-06-14T09:09:41.850004+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Lipella Pharmaceuticals director David Battleman resigns effective June 17, 2023

## Summary
- Dr. David Battleman notified the Board on May 30, 2023 of his resignation as director.
- Resignation effective June 17, 2023, and not due to any dispute or disagreement with the Company.
- No replacement director has been announced as of the filing date.

## SEC filing metadata
- accession: 0001753926-23-000765
- form_type: 8-K
- ticker: LIPO
- cik: 0001347242
- company_name: LIPELLA PHARMACEUTICALS INC.
- filed_at: 2023-06-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347242/000175392623000765/0001753926-23-000765-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347242/000175392623000765/g083578_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-23-000765
- JSON: https://secwatch.observer/filing/0001753926-23-000765.json
- Plain text: https://secwatch.observer/filing/0001753926-23-000765.txt

## Key facts
- Executive change
  David Battleman resigned as Director at LIPELLA PHARMACEUTICALS INC..
  - Action: resigned
  - Role: Director
  source text: On May 30, 2023, Dr. David Battleman informed the board of directors, or the Board, of Lipella Pharmaceuticals Inc. (the “Company”) that he will resign from the Board, effective June 17, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347242/000175392623000765/0001753926-23-000765-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.